Exact Sciences has announced a major milestone: its Oncodetect™ MRD test for colorectal cancer has secured Medicare coverage through CMS’s MolDX program. The test can now be used serially in patients with stage II, III, and resectable stage IV CRC over a five-year period for adjuvant and recurrence monitoring.
Why it matters: The highly sensitive, tumor-informed test tracks up to 200 ctDNA variants and can detect signs of cancer recurrence up to two years earlier than imaging alone. This opens the door to more personalized and timely treatment for millions of Americans eligible for MRD testing across solid tumors.